Skip to main content

torvutatug samrotecan

Generic: Torvutatug Samrotecan

torvutatug samrotecan: 5 clinical trials tracked.

torvutatug samrotecan evidence translation

What we can confirm

5 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about torvutatug samrotecan, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 1 study sponsors
Clinical Trial Registry Records (5)

A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)

NCT07816666Registry updated 2026-09-14·Phase 3·AZN
Not yet recruiting

Primary endpoint: Progression-Free Survival (PFS)

InterventionalRandomizedopen600 targetStarted 2026-09Completion 2031-1050 sites · Australia, Brazil, Canada, China…AstraZeneca

A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan in Combination With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Treatment in Participants With Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-02)

NCT07851025Registry updated 2026-10-01·Phase 3·AZN
Recruiting

Primary endpoint: Progression Free Survival (PFS)

InterventionalRandomizedsingle950 targetStarted 2026-09Completion 2033-08186 sites · Argentina, Australia, Brazil, Bulgaria…AstraZeneca

An Open-label, Fixed Sequence Phase I Study to Evaluate the Effect of Itraconazole (a Strong CYP3A Inhibitor) on the Pharmacokinetics of AZ14170132, the TOP1 Inhibitor Payload of the Antibody Drug Conjugate AZD5335, in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT07402915Registry updated 2026-09-29·Phase 1·AZN
Recruiting

Primary endpoint: Area under curve from time 0 to time 17 days (AUC0-17days)

Interventionalopen32 targetStarted 2026-01Completion 2027-109 sites · Georgia, Ireland, Portugal, SpainAstraZeneca

A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

NCT07218809Registry updated 2026-07-21·Phase 3·AZN
Recruiting

Primary endpoint: Progression free Survival (PFS)

InterventionalRandomizedsingle1,100 targetStarted 2025-12Completion 2029-1250 sites · Australia, United StatesAstraZeneca

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

NCT05797168Registry updated 2026-10-05·Phase 1/Phase 2·AZN
Recruiting

Primary endpoint: Number of participants with adverse events/serious adverse events

InterventionalRandomizedopen622 targetStarted 2023-06Completion 2028-0860 sites · Australia, Canada, China, Germany…AstraZeneca